Description
Brentuximab vedotin associated with durable remissions and long-term survival in patients with relapsed/ refractory Hodgkins’ lymphoma
€3.03
Brentuximab vedotin associated with durable remissions and long-term survival in patients with relapsed/ refractory Hodgkins’ lymphoma
You must be logged in to post a review.
Reviews
There are no reviews yet.